Chlebowski, R T <br/><br/>
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jun 1999 
 - 1939-55 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1999.17.6.1939  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anticarcinogenic Agents--adverse effects<br/>Bone Density--drug effects<br/>Breast Neoplasms--epidemiology<br/>Cardiovascular Diseases--epidemiology<br/>Cataract--epidemiology<br/>Endometrial Neoplasms--chemically induced<br/>Estrogen Antagonists--adverse effects<br/>Expert Testimony<br/>Female<br/>Humans<br/>Incidence<br/>Menopause--drug effects<br/>Raloxifene Hydrochloride--adverse effects<br/>Randomized Controlled Trials as Topic<br/>Risk Assessment<br/>Tamoxifen--adverse effects